Skip to main content
XBIT logo

XBIT · XBiotech Inc.

Track XBIT — free
$2.02 +0.02 (+1.00%) At close · Oct 20
Market Cap
$61.59M
Shares
30.49M
Volume · Oct 20 41.23K Avg daily vol (3M) 48.09K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.02 Open$2.03 Day$1.99–2.08 52W close$2.00–2.94 Avg vol 30d51K Short int328K · 1.1% float · 10.0d Short vol51% DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$45.13M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 717.5%
FCF yield
-65.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$109.53M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.5%
Year over year · more shares
Price change (1Y)
-19.7%
Trailing year
Short interest
1.1%
Latest settlement · 10.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −14%
below
Price vs 50-day avg −9%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −20%
trailing
YTD return −15%
this year
Relative strength −28%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.08% of float · ▼ -5.5% MoM · 10.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
37 holders — near 3-yr low, contrarian setup
Squeeze score 56
elevated · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
EPS growth −18%
Y/Y
Free cash flow $-40.2M
Buyback $420.0M
authorized
Balance sheet $125.6M
net cash
Quant / Vol
risk profile
High
Volatility 45%
annualized · 1-yr
Max drawdown −32%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.08% of float · ▼ -5.5% MoM · 10.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
37 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2 Now $2 · 2% Range high $3
vs 200-day avg -14% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
XBIT
XBiotech Inc.
this stock
$61.59M -15.5% -100.0% — 1.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
$90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
$80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
$66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
37
% held
7.0%
Net QoQ
+115.9K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
19
View
Short & Settlement
Short Interest Falling
Shares short
328.1K
Days to cover
10.0d
Change
-19.1K sh
View
Short Volume
Short vol %
51%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
617
Value
$1.3K
As of
Sep 23, 2026
View
Off-Exchange
Off-exchange %
37.3%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-45.5M
EPS diluted
$-1.49
View
Buybacks
Authorized
$420.0M
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Oct 2, 2026
This year
5
View
Earnings & Events
Investor Relations
Latest news
XBiotech Announces Positive Phase…
Published
Oct 19, 2026
View

Performance

5D 20D 120D MTD YTD
XBIT -6.5% -7.3% -19.8% -7.8% -15.5%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -5.3% -6.8% -27.9% -8.6% -28.3%

Capital returns

Buyback program · as of Jan 4, 2020
Authorized
$420.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1626878 CUSIP 98400H102 13F (30d) 1 filings 1 filers Visit website Investor relations